To deepen the collaboration between Shenzhen and Hong Kong in the stem cell technology industry and promote the development of cutting-edge medical technologies, the "Shenzhen-Hong Kong Stem Cell Technology Industry Exchange Event," jointly organized by the Shenzhen Municipal Office of Pharmaceutical and Medical Device Industry and the Shenzhen Qianhai Administrative Committee, was grandly held at the Starlight Walk in Tsim Sha Tsui, Hong Kong on April 22,2025. The event brought together representatives from government agencies, leading enterprises in Shenzhen, Hong Kong industry associations, and Hong Kong universities to explore new opportunities in the field of stem cells. Professor Shi Yuanyuan, Chairman of our company, served as a keynote speaker, sharing research achievements, innovative practices, and future prospects in the cell and gene therapy industry.

At the exchange meeting, Professor Shi Yuanyuan provided a detailed introduction to the core technologies, products and services, research achievements, clinical progress, as well as the technical advantages of stem cells, NK cells, and exosomes at Shenzhen Cell Valley. Leveraging its independently developed SDAP full-process industrialization technology, Shenzhen Cell Valley has achieved breakthrough progress in the field of cell therapy, successfully overcoming the challenge of large-scale production of allogeneic NK cells, significantly enhancing production efficiency. Additionally, Shenzhen Cell Valley implements quality control throughout the exosome production process in accordance with GMP standards. Its independently developed "Umbilical Mesenchymal Stem Cell Vesicles" (INCI number: 38292) (INCI name: Umbilical Mesenchymal Stem Cell Vesicles, trade name: CVEXSOTM) has been officially approved by the International Cosmetic Ingredient Naming Committee (INC) and included in the "International Cosmetic Ingredient Dictionary and Manual." Professor Shi Yuanyuan stated that Shenzhen Cell Valley has systematically addressed the three major pain points in cell therapy—difficult mass production, high costs, and weak quality control—through a three-dimensional approach of "technological innovation + process upgrading + full-chain quality control." The company has now established a complete industrial closed loop from R&D to clinical translation, laying a solid foundation for the development of the cell and gene therapy industry.

。